Muir-Torre Syndrome

  • Adam J. Luber
  • Joshua A. Zeichner


Muir-Torre syndrome (MTS) is a rare, autosomal dominant genodermatosis characterized by sebaceous neoplasms, keratoacanthomas, and visceral malignancies [1, 2]. MTS is a phenotypic subset of hereditary nonpolyposis colorectal cancer (HNPCC) caused by mutations in mismatch repair genes associated with microsatellite instability [3]. Due to the increased risk in developing visceral malignancies, it is important that the proper diagnosis to be made as early as possible and family members be evaluated for MTS and its associated cancers.


Basal Cell Carcinoma Hereditary Nonpolyposis Colorectal Cancer Mismatch Repair Gene Sebaceous Carcinoma MutS Homolog 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol. 1995;33(1):90–104.PubMedCrossRefGoogle Scholar
  2. 2.
    Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol. 2005;6(12):980–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Curry ML, Eng W, Lund K, Paek D, Cockerell CJ. Muir-Torre syndrome: role of the dermatopathologist in diagnosis. Am J Dermatopathol. 2004;26(3):217–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Muir EG, Bell AJ, Barlow KA. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Br J Surg. 1967;54(3):191–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Torre D. Multiple sebaceous tumors. Arch Dermatol. 1968;98(5):549–51.PubMedCrossRefGoogle Scholar
  6. 6.
    Fahmy A, Burgdorf WH, Schosser RH, Pitha J. Muir-Torre syndrome: report of a case and reevaluation of the dermatopathologic features. Cancer. 1982;49(9):1898–903.PubMedCrossRefGoogle Scholar
  7. 7.
    Higgins HJ, Voutsalath M, Holland JM. Muir-Torre syndrome: a case report. J Clin Aesthet Dermatol. 2009;2(8):30–2.PubMedGoogle Scholar
  8. 8.
    Cohen PR, Kohn SR, Kurzrock R. Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med. 1991;90(5):606–13.PubMedCrossRefGoogle Scholar
  9. 9.
    South CD, Hampel H, Comeras I, Westman JA, Frankel WL, De la Chapelle A. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst. 2008; 100(4):277–81.PubMedCrossRefGoogle Scholar
  10. 10.
    Eisen DB, Michael DJ. Sebaceous lesions and their associated syndromes: part II. J Am Acad Dermatol. 2009;61(4):563–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Mangold E, Rahner N, Friedrichs N, et al. MSH6 mutation in Muir-Torre syndrome: could this be a rare finding? Br J Dermatol. 2007;156(1):158–62.PubMedCrossRefGoogle Scholar
  12. 12.
    Lynch HT, Fusaro RM. The Muir-Torre syndrome in kindreds with hereditary nonpolyposis colorectal cancer (Lynch syndrome): a classic obligation in preventive medicine. J Am Acad Dermatol. 1999;41(5):797–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Hare HH, Mahendraker N, Sarwate S, Tangella K. Muir-Torre syndrome: a rare but important disorder. Cutis. 2008;82(4):252–6.PubMedGoogle Scholar
  14. 14.
    Marazza G, Masouyé I, Taylor S, et al. An illustrative case of Muir-Torre syndrome: contribution of immunohistochemical analysis in identifying indicator sebaceous lesions. Arch Dermatol. 2006;142(8):1039–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Bayliss SJ, Berk DR. Muir-Torre syndrome. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. St. Louis, MO: Elsevier; 2012.Google Scholar
  16. 16.
    Eisen DB, Michael DJ. Sebaceous lesions and their associated syndromes: part I. J Am Acad Dermatol. 2009;61(4):549–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Dores GM, Curtis RE, Toro JR, Devesa SS, Fraumeni Jr JF. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer. 2008;113(12):3372–81.PubMedCrossRefGoogle Scholar
  18. 18.
    Akhtar S, Oza KK, Khan SA, Wright J. Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol. 1999;41(5):681–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Cohen PR. Muir-Torre syndrome in patients with hematologic malignancies. Am J Hematol. 1992;40(1):64–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Poleksic S. Keratoacanthoma and multiple carcinomas. Br J Dermatol. 1974;91(4):461–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Pardo FS, Wang CC, Albert D, Stracher MA. Sebaceous carcinoma of the ocular adnexa: radiotherapeutic management. Int J Radiat Oncol Biol Phys. 1989;17(3):643–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Hata M, Koike I, Omura M, Maegawa J, Ogino I, Inoue T. Noninvasive and curative radiation therapy for sebaceous carcinoma of the eyelid. Int J Radiat Oncol Biol Phys. 2012;82(2): 605–11.PubMedCrossRefGoogle Scholar
  23. 23.
    Spielvogel RL, DeVillez RL, Roberts LC. Oral isotretinoin therapy for familial Muir-Torre syndrome. J Am Acad Dermatol. 1985;12(3):475–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Pettey AA, Walsh JS. Muir-Torre syndrome: a case report and review of the literature. Cutis. 2005;75(3):149–55.PubMedGoogle Scholar
  25. 25.
    Cohen PR, Kohn SR, Davis DA, Kurzrock R. Muir-Torre syndrome. Dermatol Clin. 1995; 13(1):79–89.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Adam J. Luber
    • 1
  • Joshua A. Zeichner
    • 2
  1. 1.Department of DermatologyMt Sinai HospitalNew YorkUSA
  2. 2.Department of DermatologyMt. Sinai School of MedicineNew YorkUSA

Personalised recommendations